Evaluation of the Reproducibility of a Fatigability Test Fitted to Patients With Spinal Muscular Atrophy (FANTASI-SMART)

Centre Hospitalier Universitaire de Saint Etienne

Status: Enrolling

Conditions: Infantile Spinal Muscular Atrophy; Juvenile Spinal Muscular Atrophy; Spinal Amyotrophy

Treatments: Other: Grip test; Other: Thumb test; Other: Quadriceps Intermittent Fatigue test (QIF test))

Study type: Interventional

Funder types: Other

Identifiers

NCT06562283

ANSM (Other Identifier)

23CH295

Details and patient eligibility

About

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by the degeneration of motor neurons in the anterior horn of the spinal cord, due to the absence of the SMN1 gene and the resulting lack of SMN protein. Some patients with particularly severe forms (types 0 or 1) die before the age of 2 in the absence of treatment, while others retain autonomous walking throughout their lives, with no reduction in life expectancy. Three treatments aimed at restoring SMN (TRS) protein expression have recently been approved by the US Food and Drug Administration and the European Medicines Agency (i.e. Nusinersen / Onasemnogene Abeparvovec / Risdiplam). Patients treated with TRS after the onset of symptoms (symptomatic patients) may show significant motor improvement, but retain difficulties such as muscle weakness and fatigue leading to limitations in activities of daily living. The aim of this study is to adapt a fatigability test, widely validated in its original version in different populations (QIF test), but adapted in this protocol to the motor level and low abilities of certain SMA patients. Our objectives are to determine whether these assessments are feasible in SMA patients, reproducible, and relevant for monitoring this population, either routinely or for future clinical trials.

Enrollment: 80 estimated patients

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Genetically confirmed spinal muscular atrophy
• Age ≥ 6 years
• No orthopaedic surgery in the 6 months prior to inclusion
• Informed consent signed by the patient(s) or parent(s)/legal guardian(s) and assent of the patient
• Affiliated or beneficiary of a health insurance scheme (for inclusion in France)

Exclusion criteria

• Other condition that may significantly interfere with the assessment of the SMA and which is clearly unrelated to the disease
• Other associated neurological disease
• Joint deformities that prevent correct and comfortable positioning with the various different measuring devices (thumb-index clamp, handgrip and QIF-test)
• Contraindication to transcranial magnetic stimulation

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

80 participants in 3 patient groups

Ambulatory patients (SMA-AMB)

Experimental group

Description:

The patient is said to be "ambulant" if he or she is able to walk and perform a muscle contraction test with the quadriceps.

Treatment:

Other: Quadriceps Intermittent Fatigue test (QIF test))

Other: Grip test

Non-ambulatory patients capable of effective grasping (SMA-PRE)

Experimental group

Description:

The patient is said to be "non-ambulant", with the ability to grasp the hand.

Treatment:

Other: Thumb test

Other: Grip test

Non-ambulatory patients without grasping ability (SMA-POU)

Experimental group

Description:

The patient is said to be "non-ambulant", with the ability to contract the thumb, but without the ability to grasp the hand.

Treatment:

Other: Thumb test